GlassScriptPhysician profile
Alison Bates Durham
NPI 1104089747
$2,628.61
in general payments reported to CMS, 2019-2025
15 companies · $561 in 2025
The $561 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $350 · 2023: $816 · 2024: $902 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,278.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $638.52 | 2022-2025 | Skyrizi, Humira |
| Dermavant Sciences, INC. | $504.02 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $265.16 | 2022-2024 | Sotyktu |
| Janssen Scientific Affairs, LLC | $262.03 | 2023-2025 | Tremfya |
| Leo Pharma INC. | $158.30 | 2022-2023 | Adbry |
| Incyte Corporation | $154.49 | 2023-2024 | Opzelura |
| Regeneron Pharmaceuticals, INC. | $149.24 | 2025 | Libtayo |
| Arcutis Biotherapeutics, INC. | $125.71 | 2024 | Zoryve |
| Krystal Biotech INC | $114.05 | 2023 | Vyjuvek |
| Biofrontera INC. | $86.50 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $68.45 | 2022 | |
| Pfizer INC. | $34.49 | 2023 | |
| Organon LLC | $25.98 | 2025 | Vtama |
| Lilly USA, LLC | $21.39 | 2022 | |
| Almirall LLC | $20.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Durham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.